Cargando…
Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era
The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentia...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443007/ https://www.ncbi.nlm.nih.gov/pubmed/32884277 http://dx.doi.org/10.2147/TCRM.S261753 |
_version_ | 1783573549152206848 |
---|---|
author | Hamdy, Sherif M Abdel-Naseer, Maged Shehata, Hatem S Shalaby, Nevin M Hassan, Amr Elmazny, Alaa Shaker, Ehab Nada, Mona A F Ahmed, Sandra M Hegazy, Mohamed I Mourad, Husam S Abdelalim, Ahmed Magdy, Rehab Othman, Alshimaa S Mekkawy, Doaa A Kishk, Nirmeen A |
author_facet | Hamdy, Sherif M Abdel-Naseer, Maged Shehata, Hatem S Shalaby, Nevin M Hassan, Amr Elmazny, Alaa Shaker, Ehab Nada, Mona A F Ahmed, Sandra M Hegazy, Mohamed I Mourad, Husam S Abdelalim, Ahmed Magdy, Rehab Othman, Alshimaa S Mekkawy, Doaa A Kishk, Nirmeen A |
author_sort | Hamdy, Sherif M |
collection | PubMed |
description | The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era. |
format | Online Article Text |
id | pubmed-7443007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74430072020-09-02 Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era Hamdy, Sherif M Abdel-Naseer, Maged Shehata, Hatem S Shalaby, Nevin M Hassan, Amr Elmazny, Alaa Shaker, Ehab Nada, Mona A F Ahmed, Sandra M Hegazy, Mohamed I Mourad, Husam S Abdelalim, Ahmed Magdy, Rehab Othman, Alshimaa S Mekkawy, Doaa A Kishk, Nirmeen A Ther Clin Risk Manag Review The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era. Dove 2020-08-17 /pmc/articles/PMC7443007/ /pubmed/32884277 http://dx.doi.org/10.2147/TCRM.S261753 Text en © 2020 Hamdy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Hamdy, Sherif M Abdel-Naseer, Maged Shehata, Hatem S Shalaby, Nevin M Hassan, Amr Elmazny, Alaa Shaker, Ehab Nada, Mona A F Ahmed, Sandra M Hegazy, Mohamed I Mourad, Husam S Abdelalim, Ahmed Magdy, Rehab Othman, Alshimaa S Mekkawy, Doaa A Kishk, Nirmeen A Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title | Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title_full | Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title_fullStr | Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title_full_unstemmed | Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title_short | Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era |
title_sort | management strategies of patients with neuromyelitis optica spectrum disorder during the covid-19 pandemic era |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443007/ https://www.ncbi.nlm.nih.gov/pubmed/32884277 http://dx.doi.org/10.2147/TCRM.S261753 |
work_keys_str_mv | AT hamdysherifm managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT abdelnaseermaged managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT shehatahatems managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT shalabynevinm managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT hassanamr managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT elmaznyalaa managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT shakerehab managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT nadamonaaf managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT ahmedsandram managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT hegazymohamedi managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT mouradhusams managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT abdelalimahmed managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT magdyrehab managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT othmanalshimaas managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT mekkawydoaaa managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera AT kishknirmeena managementstrategiesofpatientswithneuromyelitisopticaspectrumdisorderduringthecovid19pandemicera |